Re: Shareholder's Meeting
They can't really say anything about a BO or partnership *unless and until* it's a done deal. I'm sure they'd love either at the right price, but obviously that price hasn't come along. So nothing to say & no timeline. In the meantime, they must proceed as if going 100% alone is the best approach (true or not).
And they replaced CEO & commercial head, and reps are out there, so A sales are going to be what they'll be. Depends on hospital demand.
I'd ask: "Despite 2 approved drugs & another more developed, the stock is trading at the same level as *5 years ago*, what do you feel is responsible for zero price appreciation?"
There's the 2023 genetic date, will there be any major catalyst before then? Something beyond linear sales growth of 1 drug?
[Let them fully acknowledge their @* sales to date of both drugs]
This is where it's great to be mgmt, with option grants at low prices for years & years, and sucks to be an investor in this dung heap. If it goes to 2023 and finally doubles, investors over 10 years will have gotten a 7% return in a raging bull market. But all of management will have accumulated a couple hundred thousand shares via option grants. Say the price goes 26 to 52 by 2023. Mgmt walks away with 200,000 x (52-26), or $5m each, that's if they do next to nothing but keep the doors open (their current approach).